CRIA Trials in Progress
Study of 3 Different Drug Combinations in Drug-Naïve, HIV+ Individuals (Currently Enrolling)
CRIA is participating in a 96-week study sponsored by Glaxo Wellcome. This study will look at the effect of three different anti-HIV drug combinations on people infected with HIV. Some individuals with HIV experience changes in body shape as a result of fat redistribution. The primary purpose of this clinical trial is to study this effect. The study is for adults who are HIV-1+, have a CD4+ lymphocyte cell count greater than or equal to 50 cells/mm3, have a viral load greater than 1,000 copies/mL and less than 200,000 copies/mL, and have NOT received anti-HIV drugs in the past or have very limited use of certain anti-HIV drugs. Participants will be reimbursed $15 plus a $3 MetroCard per visit after enrollment.
Topical Aspirin for Peripheral Neuropathy (Currently Enrolling)
CRIA is now enrolling a 5-week double-blinded study looking at the efficacy of topical aspirin to treat painful sensory peripheral neuropathies in people with HIV. Over the course of the trial, participants will be given two separate bottles of solution: one with aspirin in diethyl ether, another with an inactive placebo in diethyl ether. The order in which these bottles will be provided is randomized. The solution will be applied on the skin over the painful area 3 times a day. HIV-infected adults with painful sensory neuropathy that has been present for at least a month are eligible. There will be a total of 5 study visits. Study participants will be reimbursed $15 plus a $3 MetroCard per visit after enrollment.
SAM-e for Depression in HIV+ Individuals (Currently Enrolling)
Enrollment has begun at CRIA for an 8-week open-label study of the efficacy and safety of using S-adenosylmethionine (SAM-e) to treat depression in HIV+ individuals. SAM-e is a naturally occurring compound that is sold as a food supplement in this country. HIV-infected adults with diagnosed clinical depression may be eligible for this study. There will be a total of 7 study visits.
Metabolic Effects of Protease Inhibitors
CRIA is conducting a study in cooperation with Dr. Ann Danoff, Chief of Endocrinology at Bronx-Lebanon Hospital, to examine whether there is an association between short-term antiretroviral therapy (ARV) and glucose intolerance, hyperlipidemia, or body habitus changes. The trial will study HIV negative persons who have sustained needle stick injuries, before and at the conclusion of a course of ARV prophylactic therapy. This study will provide the opportunity to examine the impact of protease inhibitor therapy independent of HIV infection.
For more information on any of these studies, please call Dr. Irene Cergnul or Dr. Douglas Mendez at (212) 924-3934, or visit our Web site (www.criany.org).
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.